UPDATE: Goldman Sachs Raises Target to $28 on Carefusion

Goldman Sachs raises its target price to $28 on Neutral-rated Carefusion

on incrementally higher confidence in the company's long term outlook. Goldman Sachs says, "Longer-term, the company remains focused on building a foundation for growth – improving/streamlining infrastructure (should reduce SG&A) and bolstering the pipeline (through both internal R&D and M&A). We see strategic activity as a key driver for the stock." CFN closed at $25.24 a share yesterday.